Johnson & Johnson Monarch robot earns regulatory nod in China
Johnson & Johnson MedTech (NYSE: JNJ) announced that its Monarch platform and Monarch bronchoscope obtained regulatory approval in China.
Stay updated with breaking news from Johnson Medtech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Johnson & Johnson MedTech (NYSE: JNJ) announced that its Monarch platform and Monarch bronchoscope obtained regulatory approval in China.
/PRNewswire/ -- Johnson & Johnson MedTech* today announced that the MONARCH Platform and MONARCH Bronchoscope have obtained regulatory approval in China. The...
Johnson & Johnson MedTech plans to submit its Ottava robotic surgical system for an FDA investigational device exemption in 2024. It will join J&J's portfolio o
The surgical robot, Ottava, incorporates four robotic arms into a standard size surgical table and has the ability to reposition a patient without interrupting the surgical procedure, the company said. Intuitive Surgical with its surgical robot da Vinci has been a market leader in the robotic surgery space, while Medtronic Plc is also attempting to enter the market with robotic surgical system Hugo.
Johnson & Johnson MedTech says it will submit its new Ottava surgical robot to the FDA.